BRANFORD, Conn., April 12 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007. A total of five poster presentations on belinostat (PXD101) and one poster presentation on velafermin will be made during the conference.
Belinostat (PXD101), HDAC inhibitor for the treatment of cancer: -- “Activity of PXD101, an HDAC inhibitor, used alone or in combination with 5-FU in preclinical gastroesophageal studies,” (Abstract #691) during the conference’s HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall, Poster Section 28 on Poster Board #14 -- “Gene expression screen in cell panel selected for varying sensitivity towards the Histone Deacetylase inhibitor (HDACi) PXD101 reveals potential predictors of HDACi sensitivity,” (Abstract #687) during the conference’s HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall, Poster Section 28 on Poster Board #10 -- “The effect of the histone deacetylase inhibitor (HDACi) PXD101 on cell growth and expression of viral and host genes in hepatitis B virus (HBV)-carrying hepatocellular carcinoma (HCC) cell lines,” (Abstract #696) during the conference’s HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall, Poster Section 28 on Poster Board #19 -- “The histone deacetylase (HDAC) inhibitor PXD101 suppresses bladder cancer cell growth both in-vitro and in-vivo,” (Abstract #2211) during the conference’s Mouse Models of Cancer 2: Therapeutic Approaches poster session on Monday, April 16th in the Exhibit Hall, Poster Section 23 on Poster Board #9 -- “The HDAC inhibitors romidepsin and PXD101 interact synergistically with Bortezomib in human chronic lymphocytic leukemia (CLL) cells in association with NF-.B inactivation,” (Abstract #1835) during the conference’s Targeted Agents and Other Novel Therapies poster session on Monday, April 16th in the Exhibit Hall, Poster Section 7 on Poster Board #21 Velafermin, protein for the prevention of severe oral mucositis: -- “Velafermin (rhFGF-20) reduces fractionated radiation- induced oral mucositis in hamsters,” (Abstract #3758) during the conference’s Cytosolic Signaling 2 poster session on Tuesday, April 17th in the Exhibit Hall, Poster Section 16 on Poster Board #15. About CuraGen
CuraGen Corporation is a biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody- drug conjugate and small molecule therapeutics. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of patients with cancer and inflammatory diseases. CuraGen is focused on bringing velafermin, belinostat and CR011-vcMMAE through clinical development, and maintains a portfolio of earlier-stage compounds that have the potential to treat cancer and inflammatory diseases. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit www.curagen.com.
Safe Harbor
Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospect may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen’s drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen’s stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen’s history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen’s products, processes and technologies, CuraGen’s ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in the Company’s Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission under the section “Risk Factors,” as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CRGN-P Contact: Glenn Schulman, Pharm.D. Director of Investor Relations gschulman@curagen.com (888) 436-6642
CuraGen Corporation
CONTACT: Glenn Schulman, Pharm.D., Director of Investor Relations ofCuraGen Corporation, +1-888-436-6642 or gschulman@curagen.com
Web site: http://www.curagen.com/
